|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/09/17 Unilife Corp 10-Q 12/31/16 77:8.1M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Unis-10Q2-20161231 HTML 656K
2: EX-10.1 Material Contract HTML 187K
3: EX-10.2 Material Contract HTML 119K
4: EX-10.3 Material Contract HTML 119K
5: EX-10.4 Material Contract HTML 47K
6: EX-10.5 Material Contract HTML 47K
7: EX-15 Letter re: Unaudited Interim Financial Info HTML 23K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
11: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
18: R1 Document and Entity Information HTML 43K
19: R2 Consolidated Balance Sheets HTML 113K
20: R3 Consolidated Balance Sheets (Parenthetical) HTML 56K
21: R4 Consolidated Statements of Operations and HTML 64K
Comprehensive Loss
22: R5 Consolidated Statement of Stockholders' Deficit HTML 53K
23: R6 Consolidated Statements of Cash Flows HTML 128K
24: R7 Description of Business and Unaudited Financial HTML 30K
Statements
25: R8 Internal Investigation and Listed Exchange Update HTML 34K
26: R9 Liquidity HTML 41K
27: R10 Summary of Significant Accounting Policies HTML 83K
28: R11 Equity Transactions and Share-Based Compensation HTML 165K
29: R12 Property, Plant and Equipment HTML 69K
30: R13 Goodwill HTML 32K
31: R14 Accrued Expenses HTML 50K
32: R15 Long-Term Debt HTML 109K
33: R16 Net Loss Per Share HTML 103K
34: R17 Contingencies HTML 52K
35: R18 Revenue HTML 56K
36: R19 Change in Board of Directors HTML 25K
37: R20 Fair Value Measurements HTML 126K
38: R21 Sublease HTML 46K
39: R22 Related Party Transactions HTML 36K
40: R23 Summary of Significant Accounting Policies HTML 107K
(Policies)
41: R24 Summary of Significant Accounting Policies HTML 29K
(Tables)
42: R25 Equity Transactions and Share-Based Compensation HTML 135K
(Tables)
43: R26 Property, Plant and Equipment (Tables) HTML 63K
44: R27 Goodwill (Tables) HTML 32K
45: R28 Accrued Expenses (Tables) HTML 49K
46: R29 Long-Term Debt (Tables) HTML 67K
47: R30 Net Loss Per Share (Tables) HTML 98K
48: R31 Fair Value Measurements (Tables) HTML 121K
49: R32 Sublease (Tables) HTML 42K
50: R33 Internal Investigation and Listed Exchange Update HTML 38K
- Additional Information (Detail)
51: R34 Liquidity - Additional Information (Detail) HTML 104K
52: R35 Summary of Significant Accounting Policies - HTML 41K
Estimated Useful Life of Asset (Detail)
53: R36 Summary of Significant Accounting Policies - HTML 48K
Additional Information (Detail)
54: R37 Equity Transactions and Share-Based Compensation - HTML 215K
Additional Information (Detail)
55: R38 Equity Transactions and Share-Based Compensation - HTML 49K
Schedule of Stock Options Activity by Employees
and Directors (Detail)
56: R39 Equity Transactions and Share-Based Compensation - HTML 44K
Schedule of Stock Options Activity by Other than
Employees and Directors (Detail)
57: R40 Equity Transactions and Share-Based Compensation - HTML 46K
Summary of Activity Related to Awards of
Restricted Stock and Restricted Stock Units
(Detail)
58: R41 Property, Plant and Equipment - Components of HTML 48K
Property, Plant and Equipment (Detail)
59: R42 Property, Plant and Equipment - Additional HTML 33K
Information (Detail)
60: R43 Goodwill - Changes in Carrying Amount of Goodwill HTML 27K
(Detail)
61: R44 Accrued Expenses - Components of Accrued Expenses HTML 37K
(Detail)
62: R45 Accrued Expenses - Additional Information (Detail) HTML 24K
63: R46 Long-Term Debt - Components of Long-Term Debt HTML 50K
(Detail)
64: R47 Long-Term Debt - Components of Long-Term Debt HTML 40K
(Parenthetical) (Detail)
65: R48 Long-Term Debt - Additional Information (Detail) HTML 284K
66: R49 Net Loss Per Share - Net Loss Per Share (Detail) HTML 44K
67: R50 Net Loss Per Share - Additional Information HTML 38K
(Detail)
68: R51 Contingencies - Additional Information (Detail) HTML 59K
69: R52 Revenue - Additional Information (Detail) HTML 120K
70: R53 Fair Value Measurements - Fair Value Measured on HTML 37K
Recurring Basis (Detail)
71: R54 Fair Value Measurements - Schedule of Changes in HTML 39K
Fair Value of Level 3 Financial Instruments
(Detail)
72: R55 Sublease - Additional Information (Detail) HTML 50K
73: R56 Sublease - Summary of Liability and Cash Costs HTML 38K
Paid or Settled in Connection With Sublease, Total
Charges Expected to be Incurred and Cumulative
Charges Incurred to Date (Detail)
74: R57 Related Party Transactions - Additional HTML 78K
Information (Detail)
76: XML IDEA XML File -- Filing Summary XML 128K
75: EXCEL IDEA Workbook of Financial Reports XLSX 101K
12: EX-101.INS XBRL Instance -- unis-20161231 XML 2.00M
14: EX-101.CAL XBRL Calculations -- unis-20161231_cal XML 144K
15: EX-101.DEF XBRL Definitions -- unis-20161231_def XML 706K
16: EX-101.LAB XBRL Labels -- unis-20161231_lab XML 1.40M
17: EX-101.PRE XBRL Presentations -- unis-20161231_pre XML 1.03M
13: EX-101.SCH XBRL Schema -- unis-20161231 XSD 219K
77: ZIP XBRL Zipped Folder -- 0001564590-17-001314-xbrl Zip 190K
Exhibit 10.5
tenth AMENDMENT TO CREDIT AGREEMENT
This Tenth AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is made and entered into as of December 20, 2016 by and among Unilife Medical Solutions, Inc., a Delaware corporation (the “Borrower”), the other Creditor Obligors party hereto and ROS Acquisition Offshore LP, a Cayman Islands exempted limited partnership (in its capacity as Lender and Collateral Agent, the “Lender”).
WHEREAS, the Borrower and the Lender are party to that certain Credit Agreement, dated as of March 12, 2014 (as amended from time to time, the “Credit Agreement”), pursuant to which the Lender has extended credit to the Borrower on the terms set forth therein;
WHEREAS, the Borrower has advised the Lender that Holdings intends to issue $5,000,000 in Amgen Convertible Notes on December 20, 2016;
WHEREAS, the Borrower has requested that the Lender amend the Credit Agreement, as more fully described herein; and
WHEREAS, the Lender is willing to agree to such amendment, but only upon the terms and subject to the conditions set forth herein.
NOW, THEREFORE, in consideration of the mutual agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
1. Definitions; Loan Document. Capitalized terms used herein without definition shall have the meanings assigned to such terms in the Credit Agreement. This Amendment shall constitute a Loan Document for all purposes of the Credit Agreement and the other Loan Documents. Each reference to “hereof”, “hereunder”, “herein” and “hereby” and each other similar reference and each reference to “this Agreement” and each other similar reference contained in the Credit Agreement shall, after this Amendment becomes effective, refer to the Credit Agreement as amended hereby.
2. Consent. The Credit Obligors hereby agree that the Credit Obligors will obtain Lender’s written consent prior to closing on a transaction to sell securities of Holdings to a third party other than Amgen Inc. or any employee of Holdings or Borrower during the four-month period commencing January 1, 2017 and ending April 30, 2017.
DC: 6300829-3
(a) The following definition in Section 1.1 of the Credit Agreement is hereby amended and restated in its entirety as follows:
“Amgen Convertible Notes” means the 6.0% Senior Secured Convertible Notes due 2023 issued by Holdings and Borrower pursuant to the Amgen Securities Purchase Agreement in the principal amount of $30,000,000 on February 22, 2016, in a principal amount of $10,600,000 on October 24, 2016, in a principal amount of $5,000,000 on December 20, 2016 and in a principal amount of $10,000,000 on January 3, 2018.
4. Conditions to Effectiveness of Amendment. This Amendment shall become effective upon receipt by:
(a) the Lender of a counterpart signature to this Amendment duly executed and delivered by the Borrower and each of the other Credit Obligors,
(b) the Credit Obligors of a counterpart signature to this Amendment duly executed and delivered by the Lender,
(c) the Borrower of $5,000,000 gross proceeds from convertible notes issued by Holdings and Borrower to Amgen Inc.
5. Expenses. The Borrower agrees to pay on demand all expenses of the Lender (including, without limitation, the fees and out-of-pocket expenses of Covington & Burling LLP, counsel to the Lender, and of local counsel, if any, who may be retained by or on behalf of the Lender) incurred in connection with the negotiation, preparation, execution and delivery of this Amendment and all other expenses of the Lender remaining unpaid as of the date hereof.
6. No Implied Amendment or Waiver. Except as expressly set forth in this Amendment, this Amendment shall not, by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Lender under the Credit Agreement or the other Loan Documents, or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained in the Credit Agreement or the other Loan Documents, all of which shall continue in full force and effect. Nothing in this Amendment shall be construed to imply any willingness on the part of the Lender to agree to or grant any similar or future amendment, consent or waiver of any of the terms and conditions of the Credit Agreement or the other Loan Documents.
7. Reaffirmation of Security Interests. Subject to the Intercreditor Agreement, dated February 22, 2016, among Amgen Inc., Lender and ROS, the Credit Obligors (i) affirm that each of the security interests and liens granted in or pursuant to the Loan Documents are valid and subsisting and (ii) agree that this Amendment shall in no manner impair or otherwise adversely affect any of the security interests and liens granted in or pursuant to the Loan Documents.
-2-
8. Reaffirmation of Guarantee. Each Guarantor (a) acknowledges and consents to all of the terms and conditions of this Amendment, (b) affirms all of its obligations under the Loan Documents and (c) agrees that this Amendment and all documents executed in connection herewith do not operate to reduce or discharge the Guarantor’s obligations under the Loan Documents.
9. Press Release. No Credit Obligor shall, and each Credit Obligor shall instruct its Affiliates not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Amendment or the subject matter hereof without the prior consent of the Lender (which consent shall not be unnecessarily withheld or delayed), except as may be required by applicable Law (in which case the Credit Obligor required to make the release or statement shall allow the Lender reasonable time to comment on such release or statement in advance of such issuance).
10. Waiver and Release. TO INDUCE THE LENDER TO AGREE TO THE TERMS OF THIS AMENDMENT, EACH Credit Obligor REPRESENTS AND WARRANTS THAT AS OF THE DATE HEREOF THERE ARE NO CLAIMS OR OFFSETS AGAINST OR RIGHTS OF RECOUPMENT WITH RESPECT TO OR DEFENSES OR COUNTERCLAIMS TO ITS OBLIGATIONS UNDER THE LOAN DOCUMENTS AND IN ACCORDANCE THEREWITH IT:
(a) WAIVES ANY AND ALL SUCH CLAIMS, OFFSETS, RIGHTS OF RECOUPMENT, DEFENSES OR COUNTERCLAIMS, WHETHER KNOWN OR UNKNOWN, ARISING PRIOR TO THE DATE HEREOF; AND
(b) RELEASES AND DISCHARGES THE LENDER, ITS AFFILIATES AND ITS AND THEIR OFFICERS, DIRECTORS, EMPLOYEES, AGENTS, SHAREHOLDERS AND ATTORNEYS (COLLECTIVELY THE “RELEASED PARTIES”) FROM ANY AND ALL OBLIGATIONS, INDEBTEDNESS, LIABILITIES, CLAIMS, RIGHTS, CAUSES OF ACTION OR DEMANDS WHATSOEVER, WHETHER KNOWN OR UNKNOWN, SUSPECTED OR UNSUSPECTED, IN LAW OR EQUITY, WHICH THE BORROWER EVER HAD, NOW HAS, CLAIMS TO HAVE OR MAY HAVE AGAINST ANY RELEASED PARTY ARISING PRIOR TO THE DATE HEREOF AND FROM OR IN CONNECTION WITH THE LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED THEREBY.
11. Counterparts; Governing Law. This Amendment may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of such when so executed and delivered shall be an original, but all of such counterparts shall together constitute but one and the same agreement. Delivery of an executed counterpart of a signature page of this Amendment by fax transmission or other electronic mail transmission (e.g., “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart of this Amendment. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK).
[Remainder of Page Intentionally Left Blank]
-3-
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective officers thereunto duly authorized as of the day and year first above written.
EXECUTED as a deed by each Australian Subsidiary.
|
Unilife Medical Solutions, Inc. |
|
Unilife Corporation |
||||
|
|
|
|
|
|
|
|
|
By: |
/s/ John Ryan |
|
By: |
/s/ John Ryan |
||
|
|
Name: |
|
|
Name: |
||
|
|
Title: |
President and Chief Executive Officer |
|
|
Title: |
President and Chief Executive Officer |
|
|
|
|
|
|
|
|
|
|
|
|
|
Unilife Cross Farm LLC |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ John Ryan |
|
|
|
|
|
|
|
Name: |
|
|
|
|
|
|
|
Title: |
President and Chief Executive Officer |
|
Executed by Unilife Medical Solutions Pty Limited in accordance with Section 127 of the Corporations Act 2001 |
|
|
|
|
/s/ John Ryan |
← |
← |
|
|
Signature of director
|
|
Signature of director/ (Please delete as applicable)
|
|
|
Name of director (print) |
|
Name of director/company secretary (print) |
|
|
Executed by Unitract Syringe Pty Ltd in accordance with Section 127 of the Corporations Act 2001 |
|
|
|
|
/s/ John Ryan |
← |
← |
|
|
Signature of director
|
|
Signature of director/ (Please delete as applicable)
|
|
|
Name of director (print) |
|
Name of director/company secretary (print) |
|
Signature Page to Tenth Amendment to Credit Agreement
|
ROS ACQUISITION OFFSHORE LP, as the Lender By OrbiMed Advisors LLC, its investment manager |
||
|
|
|
|
|
By: |
/s/ Samuel D. Isaly |
|
|
|
Name: |
|
|
|
Title |
Managing Member |
Signature Page to Tenth Amendment to Credit Agreement
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 1/3/18 | ||||
| 4/30/17 | ||||
| Filed on: | 2/9/17 | 8-K | ||
| 1/1/17 | ||||
| For Period end: | 12/31/16 | |||
| 12/20/16 | 8-K, 8-K/A | |||
| 10/24/16 | 10-K, 10-K/A, 10-Q, 10-Q/A, 8-K | |||
| 2/22/16 | 3, 424B5, 8-K | |||
| 3/12/14 | 8-K | |||
| List all Filings | ||||